In vitro susceptibility of urogenital Chlamydia trachomatis strains in a country with high azithromycin consumption rate
Jazyk angličtina Země Spojené státy americké Médium print-electronic
Typ dokumentu časopisecké články, práce podpořená grantem
- MeSH
- antibakteriální látky farmakologie terapeutické užití MeSH
- azithromycin farmakologie terapeutické užití MeSH
- Chlamydia trachomatis účinky léků izolace a purifikace MeSH
- chlamydiové infekce mikrobiologie MeSH
- doxycyklin farmakologie MeSH
- lidé MeSH
- mikrobiální testy citlivosti MeSH
- mužské urogenitální nemoci mikrobiologie MeSH
- spotřeba léčiv MeSH
- ženské urogenitální nemoci mikrobiologie MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
- Geografické názvy
- Chorvatsko MeSH
- Názvy látek
- antibakteriální látky MeSH
- azithromycin MeSH
- doxycyklin MeSH
Although Chlamydia trachomatis resistance is not of great concern due to its excellent sensitivity to the currently recommended first-line antibiotics (azithromycin and doxycycline), clinical treatment failures have been reported and some of them were linked to laboratory proved resistance. The aim of this study was to determine in vitro susceptibility to azithromycin and doxycycline for 24 urogenital chlamydial strains isolated in Croatia-a country with the highest consumption of azithromycin in Europe and with very high antibiotic prescription rates. Fourteen isolates from cervical swabs, nine from male urethral swabs, and one isolate from expressed prostatic secretion were tested in McCoy cell culture system. All strains were susceptible to azithromycin and doxycycline with minimal inhibitory concentration for azithromycin and doxycycline ranging from 0.064 to 0.125 μg/mL and 0.016 to 0.064 μg/mL, and minimal chlamydicidal concentration ranging from 0.064 to 2.0 μg/mL and 0.032 to 1.0 μg/mL, respectively. Since we still lack information on whether C. trachomatis is evolving in vivo in response to antibiotic selection pressure, this kind of surveillance for resistance is essential in detecting shifts in antimicrobial susceptibilities.
Zobrazit více v PubMed
Sex Transm Dis. 1998 Aug;25(7):350-2 PubMed
J Chemother. 2009 Feb;21(1):63-7 PubMed
Antimicrob Agents Chemother. 2004 Oct;48(10):3989-95 PubMed
Antimicrob Agents Chemother. 2010 Dec;54(12):5379-80 PubMed
Med Glas (Zenica). 2010 Feb;7(1):26-31 PubMed
Antimicrob Agents Chemother. 2005 Nov;49(11):4804-6 PubMed
Int J Antimicrob Agents. 2004 Aug;24(2):188-91 PubMed
Coll Antropol. 2006 Dec;30 Suppl 2:131-7 PubMed
Diagn Microbiol Infect Dis. 2001 Mar;39(3):177-9 PubMed
Antimicrob Agents Chemother. 1993 Sep;37(9):1746-8 PubMed
Chemotherapy. 2010;56(5):371-7 PubMed
Emerg Infect Dis. 2009 Jul;15(7):1088-90 PubMed
J Infect Dis. 1990 Dec;162(6):1309-15 PubMed
Antimicrob Agents Chemother. 2010 Mar;54(3):1094-101 PubMed
Croat Med J. 2010 Dec;51(6):524-33 PubMed
Folia Microbiol (Praha). 2007;52(4):437-42 PubMed
Antimicrob Agents Chemother. 2003 Feb;47(2):636-42 PubMed
J Infect Dis. 2000 Apr;181(4):1421-7 PubMed
